Heart attack risk with abacavir and didanosine.
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001315:Australia; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced*; D009656:North America; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D000099227:Abacavir
D019380:Anti-HIV Agents; D016049:Didanosine; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir